在2型糖尿病 (PIONEER 4) 中,口服赛马格卢提德与皮下利拉格卢提德和安慰剂:一个随机的,双盲的3a期试验
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
在PubMed上查看摘要
概括
此摘要是机器生成的。在2型糖尿病患者中,口服赛马格卢提德有效降低血糖和体重,与注射式利拉格卢提德没有劣势. 这为治疗糖尿病提供了一种方便的口服选择.
科学领域
- 内分泌学
- 代谢疾病
- 药理学
背景情况
- 葡萄糖类-1 (GLP-1) 受体激活剂已成为2型糖尿病的治疗方法.
- 目前的GLP-1疗法需要进行皮下注射.
- 口服塞马格卢提德是一种新型口服GLP- 1激动剂.
研究的目的
- 为了比较口服赛马格卢提德与皮下利拉格卢提德和安慰剂的疗效和安全性.
- 评估口服塞马格卢提德对糖化血红蛋白 (HbA1c) 和体重的影响.
- 评估口服赛马格卢提德在糖尿病治疗中的潜力.
主要方法
- 这是一项随机,双盲,双模拟的3A期试验,涉及711名2型糖尿病患者.
- 参与者每天服用一次口服赛马格卢提德 (14 mg),皮下注射利拉格卢提德 (1. 8 mg) 或安慰剂,持续52周.
- 主要终点:26周HbA1c的变化;次要终点:26周体重的变化.
主要成果
- 在降低HbA1c的26周,口服赛马格卢提德与利拉格卢提德没有劣势,并且优于安慰剂.
- 在26周,与利拉格卢提德和安慰剂相比,口服赛马格卢提德的体重减轻显著增加.
- 口服赛马格卢提德和皮下利拉格卢提德的不良反应发生率相似.
结论
- 在2型糖尿病中,口服塞马格卢提德有效改善血糖控制和促进体重减轻.
- 口服赛马格卢提德的安全性和耐受性与皮下利拉格卢提德相似.
- 口服塞马格卢提德为提前启动GLP-1受体激动剂治疗提供了一个有前途的替代方案.
相关概念视频
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
The placebo effect is commonly described in terms of testing the effectiveness of a new medication. Imagine that you work in a pharmaceutical company, and you think you have a new drug that is effective in treating depression. To demonstrate that your medication is effective, you run...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Like benzene, cyclobutadiene and cyclooctatetraene are cyclic compounds with alternate single and double bonds. However, their chemical behavior differs from benzene, as they are unstable and not aromatic. So, what are the structural characteristics of unsaturated compounds categorized as aromatic?
For the first time, Eric Hückel, a German chemical physicist, derived a set of structural features for a compound to be classified as aromatic. This is now known as Hückel’s rule or the 4n +...
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.